Medscape: SGLT2 Inhibitors: From Glucose-Lowering to Cardio Protection

In 2013, the first SGLT2 inhibitor drug was approved and quickly garnered attention for its effectiveness in reducing blood glucose, as well as body weight and systolic blood pressure.

Since then, the medications have gone from targeting glucose-lowering to also providing cardiac protection and heart benefits, including for diabetes-free patients with heart failure.

Mohammad Abdel Jawad, MD, a cardiology research fellow at Saint Luke’s Mid America Heart Institute and the leader of a recent study on the topic, spoke with Medscape about the potential heart benefits of SGLT2 inhibitors. read the full article here: SGLT2 Inhibitors: From Glucose-Lowering to Cardio Protection.